Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting ...

More than one in four pregnant or postpartum patients with acute stroke experience missed diagnostic opportunities (MDO).

In a phase III clinical trial in China, stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days starting within 48 hours of stroke symptoms, had a ...

In infants and toddlers who had a stroke before birth or as a newborn (28 days or younger), a treatment that combined ...

Alteplase, a “clot-buster” medication used to treat ischemic stroke, acute myocardial infarctions, and acute pulmonary ...

A new predictive tool may help identify patients at risk for poststroke dementia, potentially accelerating research and ...

In a phase III clinical trial in China, stroke patients treated intravenously with loberamisal, a novel neuroprotective ...

New analyses indicate factor VIIa could benefit a small group of patients with intracerebral hemorrhage treated very early, ...

Pharmazz, Inc. today announced the presentation of positive interim results from its ongoing Phase IV clinical study of sovateltide (Tycamzzi®) in patients with acute cerebral ischemic stroke at the ...

Clinical trial results indicate a protein, rFVIIa, may benefit certain stroke patients when administered quickly, with a focus on acute intracerebral hemorrhage treatments.

Among adults with acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA) with planned ...